Jump to main content
Jump to site search

Issue 43, 2012
Previous Article Next Article

Designing organometallic compounds for catalysis and therapy

Author affiliations

Abstract

Bioorganometallic chemistry is a rapidly developing area of research. In recent years organometallic compounds have provided a rich platform for the design of effective catalysts, e.g. for olefin metathesis and transfer hydrogenation. Electronic and steric effects are used to control both the thermodynamics and kinetics of ligand substitution and redox reactions of metal ions, especially RuII. Can similar features be incorporated into the design of targeted organometallic drugs? Such complexes offer potential for novel mechanisms of drug action through incorporation of outer-sphere recognition of targets and controlled activation features based on ligand substitution as well as metal- and ligand-based redox processes. We focus here on η6-arene, η5-cyclopentadienyl sandwich and half-sandwich complexes of FeII, RuII, OsII and IrIII with promising activity towards cancer, malaria, and other conditions.

Graphical abstract: Designing organometallic compounds for catalysis and therapy

Back to tab navigation

Article information


Submitted
31 Jan 2012
Accepted
20 Mar 2012
First published
19 Apr 2012

Chem. Commun., 2012,48, 5219-5246
Article type
Feature Article

Designing organometallic compounds for catalysis and therapy

A. L. Noffke, A. Habtemariam, A. M. Pizarro and P. J. Sadler, Chem. Commun., 2012, 48, 5219
DOI: 10.1039/C2CC30678F

Social activity

Search articles by author

Spotlight

Advertisements